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Hereditary disorders of voluntary motor neurons are individually relatively uncommon, but have the potential to provide significant insights
into motor neuron function in general and into the mechanisms underlying the more common form of sporadic Amyotrophic Lateral Sclerosis.
Recently, mutations in a number of novel genes have been associated with Lower Motor Neuron (HSPB1, HSPB8, GARS, Dynactin), Upper Motor
Neuron (Spastin, Atlastin, Paraplegin, HSP60, KIF5A, NIPA1) or mixed ALS-like phenotypes (Alsin, Senataxin, VAPB, BSCL2). In comparison to
sporadic ALS these conditions are usually associated with slow progression, but as experience increases, a wide variation in clinical phenotype has
become apparent. At the molecular level common themes are emerging that point to areas of specific vulnerability for motor neurons such as
axonal transport, endosomal trafficking and RNA processing. We review the clinical and molecular features of this diverse group of genetically
determined conditions and consider the implications for the broad group of motor neuron diseases in general.
© 2006 Elsevier B.V. All rights reserved.Keywords: Motor Neuron; Axonal transport; Hereditary motor neuropathy; Neurodegeneration; Soinal muscular atrophy1. Introduction
The selective death of motor neurons is the cardinal feature
of a number of disorders that are individually uncommon but
together result in significant morbidity in the population. The
term Motor Neuron Disease is often used interchangeably with
Amyotrophic Lateral Sclerosis (ALS) to describe the best
characterised and most common of these diseases. Although the
pattern of weakness, the balance of upper and lower motor
neuron features and the degree of extra-motor involvement may
vary, the hallmark of this clinical entity is the combination of
relentlessly progressive neurological disability and typical
autopsy findings of ubiquinated intracellular inclusions in the
surviving anterior horn motor neurons of the spinal cord. The
term ‘motor neuron disease’ could equally be used to
encompass a group of inherited disorders with their own
recognisable clinical features but in which motor neurons are
affected in relative isolation. The essential feature, the relatively⁎ Corresponding author. Department of Physiology, Anatomy and Genetics,
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doi:10.1016/j.bbadis.2006.04.003selective loss of specialised neurons in the motor output
pathway, links all these disorders but this can be obscured by a
confusing array of diagnostic nomenclatures and classifications
that emphasise the differences in clinical presentation. As a
result disorders described as forms of “ALS” show considerable
overlap with others classified as forms of Spinal Muscular
Atrophy (SMA), Hereditary Motor Neuropathy (HMN),
Hereditary Spastic Paraplegia or Charcot–Marie–Tooth Type
2 (CMT2) (Fig. 1).
Research into the molecular genetics of motor neuron
disorders has progressed rapidly in the decade since the first
description of mutations in the Superoxide Dismutase (SOD1)
gene in familial forms of ALS. As well as offering benefits to
families in the form of diagnosis, genetic counselling and more
recently reproductive options such as Pre-implantation Genetic
Diagnosis (PGD), genetic research offers the hope of providing
valuable clues into the nature of the selective vulnerability of
motor neurons that underlies both familial and sporadic forms of
these conditions. The highly specialised nature of motor
neurons has prompted researchers to suggest critical functions
that could be disrupted in MND [1]. These include the demands
on intracellular processes and axonal transport created by the
uniquely long axonal processes, the susceptibility to oxidative,
Fig. 1. Schematic of the relationship between the organisation of the motor output pathway, the diagnostic groups and individual genes associated with motor neuron
disorders. MND—motor neuron disease, UMN—upper motor neuron, LMN—lower motor neuron.
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active but non-dividing cells, and the stringent developmental
process that requires molecularly identified neurons to associate
with specific predetermined muscle fibres before the system is
refined by a process of Programmed Cell Death. Mutations in
the SOD1 gene, which account for around 20% of the familial
cases of ALS, were discovered in 1993 and it was hoped that
this would be an opening for vital insights into the molecular
processes that underlie selective vulnerability. Almost a decade
later research on SOD1 has resulted in a large amount of new
information in this area but many of the central questions
regarding the nature of this vulnerability remain unanswered.
As the revolution in molecular genetics has advanced,
positional cloning studies involving small numbers of families
with a similar phenotype, or even individual families, have
identified an increasing number of loci associated with motor
neuron degeneration. Mutations in the genes underlying many
of these loci have been demonstrated and with each new gene
discovery the cellular processes vital to motor neuron survival
are more clearly defined. This review focuses on the clinical and
molecular features of disorders in which recently described
genetic mutations have been associated with a relatively pure
motor neuron specific phenotype.
Sporadic Amyotrophic Lateral Sclerosis has an incidence of
approximately 2/100,000 per year and a prevalence of
approximately 6–7/100,000. Familial ALS, accounting for
approximately 10% of cases therefore can be estimated to
have an incidence of 2 per million per year and is therefore self-
evidently a rare disorder. The exact incidence of most of the
specific genetic disorders discussed below is unknown at
present. However, even though they are individually rare,
compared with typical ALS lifespan may be prolonged. It seems
likely that pure inherited non-ALS motor neuron disorders aremuch commoner than previously recognised and collectively
may even approach the prevalence of more typical mixed motor
and sensory forms of Charcot–Marie–Tooth disease.
2. Lower motor neuron disorders
2.1. Small Heat Shock Proteins HSPB1 and HSPB8
The Heat Shock Proteins are a phylogenetically ancient and
diverse group of proteins that contribute to cellular protection in
response to various stress stimuli. This occurs at least in part
through protection against the abnormal unfolding of proteins
[2]. The small Heat Shock Proteins (sHSPs) are a sub-group that
consists of 10 different proteins of around 27 kDa in humans
that all share a highly conserved motif named the α-crystallin
domain after the first member of the family to be characterised
[3]. In 2004, mutations in two members of this family were
found to cause an autosomal dominant progressive motor
neuropathy [4,5]. A missense mutation in HSPB1 (formerly
known as HSP27), the most widely studied of the small sHSPs,
was found in a Russian family previously linked to a locus at
7q11–q21 as well as in 5 other previously unlinked families.
While in the initial family both motor and sensory symptoms
were present, and the condition was classified as CMT2F, in all
but one of the additional families the symptoms were limited to
the motor system and the term HMN-II was used [4]. Since the
initial report an additional mutation (P182S) has also been
found in a Japanese family [6] and another (R127W) has been
found in four Chinese families who share an ancestral haplotype
[7]. Information on the clinical phenotype associated with
HSPB1 mutations is limited [7,8]. Onset of symptoms from 15
to 60 years of age has been described, typically with slowly
progressive symmetrical weakness and wasting of the distal
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as difficulty with running or walking. Lower limb symptoms
typically precede upper limb symptoms by several years. In
individuals heterozygous for the R127W mutation the average
time for progression to requiring a stick for mobility was over a
decade (range 8–20 years) and to requiring a wheelchair was
around 20 years (16–20 years) [7]. Deep tendon reflexes are
reduced or lost and no other parts of the CNS are clinically
involved. Motor symptoms predominate in all families and
sensory involvement where it occurs consists of mild loss of pin
prick and vibration sense in a stocking distribution. No clear
correlation between specific features of the phenotype and the
genotype has been found and one particular mutation (S135F)
has been found both in a family where sensory involvement is
common and another where no sensory abnormalities have been
found [4]. Electrophysiology, as well as sural nerve biopsy
findings in a single case, has been consistent with an axonal
neuronopathy [7,8] (Table 1).
HSPB8 (also known as HSP22) was identified in 2001
through its binding of HSPB1 [9]. A missense mutation in
HSPB8 was found to be responsible for the motor neuropathy
observed in a large Belgian family with HMN II in which the
locus had previously been mapped to 12q24 [5,10]. Mutations
were also found in a further 3 families with a similar phenotype
and independently in a Chinese family with a motor sensory
neuropathy previously mapped to the same region as CMT2L
[11,12]. All 5 instances involve the same amino acid residue
(lysine 141). In the originally described Belgian family the
disorder is relatively aggressive with onset of symptoms in the
distal lower limbs usually in the teens or early 1920s and
progression to complete paralysis of distal muscle groups in less
than 5 years [13]. We have observed a more benign rate of
progression in an English family with the K141E mutation.
Sensory involvement has been observed in one of the five
families, deep tendon reflexes are reduced or lost and motor
conduction velocities are maintained on electrophysiological
testing.Table 1
Genes associated with pure motor neuron phenotypes
Gene Locus Mutations (Families) Onset
SOD1 ALS1 21q22 AD >100 Adult
HSPB1 HMN 7q11 AD 5 (11) Adult
HSPB8 dHMN-II 12q24 AD 2 (5) Adult
GARS dSMA-V 7q15 AD 5 (5) Adult
DCTN1 2q13 AD 5 (5) Adult
ALSIN ALS2 2q33 AR 9 (9) Infanc
SETX ALS4 9q34 AD 3 (3) Juveni
VAPB ALS8 20q13 AD 1 (7) Adult
BSCL2 dSMA-V 11q13 AD 2 (17) Juveni
SPG4 SPG4 2p22 AD >150 Juveni
PGN SPG3A 14q11 AR 7 (7) Juveni
ATL1 SPG7 16q24 AD 19 (32) Infanc
HSP60 SPG13 2q33 AD 1 (1) Adult
KIF5A SPG10 12q13 AD 4 (4) Juveni
NIPA1 SPG6 15q11 AD 2 (6) Juveni
UMN—upper motor neuron features, LMN—lower motor neuron features, AD—aut
++—typical feature, ++—occasional feature, +—infrequent feature, U—upper limb
a Wide variation in age of onset and clinical features is seen (see text), details arA large number of studies into the cytoprotective and
oncogenic functions of the sHSPs, particularly HSPB1, have
been published (reviewed in [14]). A function shared by most of
the sHSPs is the ability to act as a molecular chaperone [15–17].
Under normal conditions, the sHSPs are found in vivo as
oligomers that can contain > 30 sub-units [18]. In the presence
of cellular stressors where conditions favour proteins adopting
non-native states and the risk of undesirable interactions such as
non-specific aggregation, the sHSPs are up-regulated and
activated through phosphorylation by specific protein kinases
[9,19–21]. In response, the oligomers dissociate allowing the
dimeric proteins to interact with a large number of potential
substrates which are maintained in a folding-competent state
until conditions allow them to undergo re-folding [22]. In
addition a number of functions have been described specifically
for HSPB1 including a direct anti-apoptotic effect [23–26],
transcriptional regulation [27,28], resistance to oxidative stress
[29–31], and a role in development, cell differentiation [23,32]
and axonal outgrowth in the CNS [33].
A directly neuroprotective role has also been attributed to
sHSPs particularly in relation to diseases where abnormal
protein accumulation is a central feature such as Alzheimer's,
Parkinson's or Huntington's Diseases (reviewed [34–36]).
Significantly for the present discussion upregulation of
HSPB1 is found in motor neurons in a mouse model of familial
ALS [37]. Transfection and over-expression of HSPB1, alone
and in association with HSP70, has also been shown to protect
neurons in culture from apoptosis associated with mutant forms
of SOD1 [38].
The reported mutations in HSPB1 are found within
conserved functional domains, all but 1 within the α-crystallin
domain. The S135F mutation, but not wild type HSPB1, has
been shown to disrupt the self assembly of neurofilament light
chains when both proteins are transiently expressed and reduce
cell survival when transfected into mouse neuroblastoma (N2a)
cells [4]. The P182L mutation is situated in the C-terminal,
outside the α-crystallin domain, in a highly conserved I–P–Ia UMN LMN Sensory Limbs Other
+++ +++ U=L FTD
+++ ++ U<L
+++ U<L
+++ ++ U>L
+ +++ U>L Bulbar/Facial FTD
y +++ ++ U≤L Bulbar
le +++ +++ + U=L
++ +++ U>L Bulbar Tremor
le ++ ++ + U>L
le +++ + + U<L Cognitive Impairment
le +++ + U<L Ataxia
y +++ U<L
+++ ++ U=L
le +++ U<L
le +++ U<L
osomal dominant, AR—autosomal recessive, FTD—frontotemporal dementia, +
, L—lower limb.
e for the most typical presentation associated with each gene.
Fig. 2. Wasting of the 1st interosseus and thenar muscles is a prominent early
feature in Silver Syndrome, associated with BSCL2 mutations; (B) dSMA-V
associated with GARS mutations.
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amino terminal interactions that underlies the formation of
dimers—the minimal functional unit of sHSPs [39]. The
mutation apparently has the effect of stabilising HSPB1 binding
resulting in prominent insoluble cytoplasmic aggregates when
expressed in mouse cortical neurons (Fig. 3). Mutant protein
sequestrates specific proteins within the cytoplasm preventing
their normal distribution down the axons. These include
wildtype HSPB1 and specific components of the axonal
cytoskeleton including the neurofilament medium chain and
p150-Dynactin (DCTN1—see below) suggesting that mutant
HSPB1 might impair axonal transport [40].
The mutations at lysine 141 in HSPB8 also increase its
binding to HSPB1 and causes cytoplasmic aggregate formation
in cell culture [5]. The residue at the equivalent position in the
α-crystallin domain has also been found to be mutated in both
αA-crystallin, and αB-crystallin in autosomal dominant
cataracts and desmin related myopathy, respectively [41,42].
A residue with positive charge (lysine, arginine or histidine) at
this site in the domain is highly conserved across both the
sHSP family and between species [2] and is known to be
essential for normal oligomer formation and chaperone
function [43]. Loss of chaperone function has been demon-
strated directly for both the K141N and K141E mutations. In
cell culture wild-type HSPB8 but not the mutant protein was
able to reduce the accumulation of insoluble protein
aggregates when co-transfected with a fragment of either
huntingtin or the androgen receptor containing expanded
polyglutamine tracts [17]. Together, these results suggest that
abnormal protein aggregation, either directly or through loss of
normal chaperone function may be central to the neuropathic
effect of HSPB1 and HSPB8 mutations. Aggregates may be
directly toxic or have an effect by disrupting essential neuronal
functions such as axonal transport, as was seen for the P182L
mutation in HSPB1.
2.2. Glycyl-tRNA Synthetase (GARS)
On first consideration a ubiquitously expressed house-
keeping gene such as the GARS gene that encodes the enzyme
Glycyl-tRNA Synthetase would seem an unlikely candidate for
a disorder specific to neurons. The enzyme catalyses the
joining, through esterification, of the amino acid glycine to the
specific subset of tRNA species that carry the corresponding
cognate anti-codon sequence prior to translation [44]. Linkage
to a locus on the short arm of chromosome 7 was identified
initially in a family with a late onset form of distal motor
neuropathy, termed distal SMA type V (dSMA-V) [45]. Later,
linkage to the same locus was also demonstrated in a family in
which both motor and sensory symptoms were present resulting
in the classification CMT2D [46]. In 2003, it was shown that in
both families, along with 3 others with similar phenotypes the
condition was due to mutations in the GARS gene [47]. Unique
mutations were found in families from North America,
Bulgaria, Mongolia, France and more recently a family from
England/Australia [47,48]. We are also aware of others from the
British population. Mutations are spread throughout the geneincluding a number lying outside any known functional domain
with no obvious hot-spots [48].
The phenotypic spectrum and pathological findings associ-
ated with GARS mutations were recently well reviewed by
Sivakumar et al. [48]. A distinctive recognisable feature is the
early prominent involvement of the hands, with wasting
particularly of the thenar eminence and first dorsal interossei
muscles found at presentation in all the cases examined (Fig. 2).
The phenotypes have been classified as dSMA-V or CMT2D
based on the presence or absence of sensory symptoms however
this appears to be simply a distinction of severity as almost half
the patients without sensory symptoms had not developed lower
limb involvement after an average of almost 20 years from the
onset of hand symptoms while all the patients with loss of
sensation had developed weakness and atrophy of peroneal and
foot muscles at an average of just over 3 years from the onset of
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tion as either dSMA or CMT2 is related to the specific mutation
found in a family. The mutations L129P, H418R and G526R
consistently result in the milder motor-limited condition,
G240R consistently gives rise to the severer form with sensory
involvement and the E71G mutation found in a large family
form Mongolia is intermediate with different individuals having
phenotypes that would be classified under both terms. Non-
penetrance may be relatively common especially in the families
where the dSMA phenotype is found [48]. Progression is slow
with loss of mobility being unusual even after several decades.
Overall, motor symptoms predominate in all cases and
weakness and wasting is limited to the distal muscles with no
other systems involved. Available electrophysiology and sural
nerve biopsy data are consistent with an axonal neuronopathy
[48].
Currently, little is known about the mechanism by which
GARS mutations affect neuronal survival. Transient expression
of tagged forms of mutantGARS protein in neuronal-like cells in
culture has not resulted in an obvious cellular phenotype in our
hands (unpublished data). It is possible that a critical loss of
function results in inadequate amounts of glycine–tRNA
conjugates resulting in an effect on the translation of other
proteins essential to motor neuron maintenance. Candidates
include the proteins containing the glycine rich CAP-gly
domain, usually found in Cytoskeletal-associated proteins
(CAPs) which provide a link between vesicles and microtubules
and have a role in axonal transport [48], or the arg-gly rich
carboxy terminal repeats that are recognised by the SMN protein
and are involved in the biogenesis of small nuclear Ribonuclear
proteins (snRNPs) [49]. Other possibilities are suggested by the
recent finding of mutations in the Tyrosyl-tRNA Synthetase
(YARS) in three families affected by a motor-sensory neuropathy
classified as Dominant Intermediate CMT1C [50]. Unlike theFig. 3. Abnormal accumulation of mutant protein is a feature of a number of inher
HSPB1, (B) mutant P182L HSPB1, (C) wildtype VAPB, (D) mutant P56S VAPB.GARS protein, expression of YARS in neuronal-like cells in
culture demonstrates concentration of the protein distally in
extending processes. A specific failure of protein translation at
critical sites such as synapses or the growth cones of developing
neurons could be a unifying mechanism underlying the
disorders associated with these two amino acid–tRNA synthe-
tases (Fig. 3).
2.3. Dynactin (DCTN1)
The dynactin complex acts as a link between dynein, the
major retrograde transport motor in axons, the microtubule
network and transported cargo vesicles in neurons (reviewed in
[51]). Disruption of this system through mutations in dynein or
components of the dynactin complex in mice results in a motor
neuron degeneration phenotype [52,53]. In 2003 a mutation in
the p150 subunit of dynactin (DCTN1) was found in a family in
which a highly unusual motor neuron disorder had been linked
to 2p13 [54]. The most common presenting symptom was
stridor due to vocal cord weakness at ages ranging from 23 to
44. Bulbar involvement, along with facial weakness was
eventually seen in all cases. Progressive weakness of distal
muscle groups was typically first apparent in the upper limbs
accompanied by muscle atrophy and reduced tendon reflexes.
There was no sensory involvement. Postmortem in 1 case
confirmed the loss of motor neurons from the anterior horn and
cranial nerve nuclei but did not show the accumulation of
neurofilament associated with anterograde transport defects in
other forms of motor neuron disease. Instead, inclusions of
accumulated dynein and dynactin were found in the cell bodies
of surviving neurons [55]. A further 4 mutations have now been
reported in families with ALS, in some cases in association with
fronto-temporal dementia, and in a small number of sporadic
ALS cases [56,57]. In these families, a greater clinicalited motor neuron disorders. Mouse cortical neurons expressing: (A) wildtype
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the initially reported family the mutation G59S was found to lie
in the highly conserved CAP-gly motif (see discussion of GARS
above) and resulted in decreased binding of DCTN1 to
microtubules, while the reported M571T and R785W mutations
lie in the predicted dynein binding domain. Although screening
for variants in dynein itself has found no association [57,58] the
p150-dynactin mutations confirm the central position of
retrograde as well as anterograde transport in motor neuron
function.
3. Mixed upper and lower motor neuron disorders
3.1. Alsin—ALS2
A distinct form of recessive juvenile ALS (designated ALS3)
with prominent facial and bulbar involvement was linked to
2q33 in 1994 in a large inbred Tunisian family [59]. Two groups
independently demonstrated that mutations in the gene Alsin
(ALS2) were responsible for this phenotype [60,61]. A total of 9
mutations, all involving frame shift or truncating mutations,
have been described, frequently in consanguineous families
[62–65]. The clinical phenotype has been divided into 3
overlapping groups. The term Infantile Ascending Hereditary
Spastic Paraplegia (IAHSP) has been applied to 6 families in
which affected individuals develop symptoms of spastic
paraplegia in the lower limbs at 1–2 years of age. Upper limb
involvement follows by the end of the first decade with bulbar
involvement becoming apparent at around the same time or
soon afterwards and leading eventually to anarthria [62,64,65].
Involvement of the extra-ocular muscles resulting in gaze
paralysis is a variable feature. The condition is severe and
progressive with loss of independent mobility by around 4–
5 years, loss of the ability to sit by the mid-teens and a reduced
life expectancy. Intellectual function is thought to be preserved
however abnormalities on MRI, including cerebral atrophy and
hyperintense signal in the internal capsule and parieto-occipital
periventricular white matter, may indicate more diffuse CNS
involvement [65]. A further 2 families in which the term
Juvenile Primary Lateral Sclerosis has been applied have
essentially the same phenotype [60,66]. Members of the large
Tunisian family in which the ALS2 locus was first mapped have
a later onset form of the disorder with initial symptoms of either
gait abnormality or pseudobulbar palsy first appearing at 3–
10 years. The range of symptoms in this family is similar to the
infantile form although the presence of amyotrophy of the lower
limbs and hands in some cases justify the classification as a
form of ALS [67].
The Alsin protein is distributed widely in the CNS and other
tissues as a highly expressed long form (6.5 kb) and a less
common short form (2.6 kb) [60]. All but one of the described
mutations affects the long form only. As predicted based on
homology Alsin has been shown to function as a guanine-
exchange factor (GEF) and is required for the activation of at
least 2 proteins with GTPase activity [68–70]. The first of these,
RAB5A, is associated with the regulation of the fusion,
internalization and trafficking of endosomal vesicles [71].Ectopically and endogenously expressed Alsin has been found
to localise to the cytoplasmic surface of endosomes and results
in the enlargement of early endosomes in vitro [68,72]. This
function is mediated by the carboxyl terminal VPS9 domain,
one of 3 GEF domains found in Alsin, and requires homo-
oligomerisation of the protein [73]. The second protein known
to be activated through the action of Alsin is Rac1 (ras-related
C3 botulinum toxin substrate 1) [69], a GTPase associated with
regulation of axonal development through signaling cues that
influence actin dynamics at the growth cone [74,75]. Alsin has
been demonstrated co-localising with Rac1 in the growth cone
and transient expression in cortical neurons stimulates neurite
outgrowth [69]. This function is mediated by the Db1
Homology and Pleckstrin Homology (DH/PH) domain—the
2nd of the 3 GEF domains. Transient expression of Alsin
protects NSC34 (motor neuron-like) cells from the toxic effect
of the mutant forms of SOD1. The use of deletion constructs
showed that this neuroprotective function is also mediated by
the DH/PH domain and does not require either the amino
terminal RCC1, or carboxy-terminal VPS9 GEF domains [76].
The null mutations responsible for ALS2 result in unstable
products that are rapidly cleared by the proteasome [72]
suggesting that complete loss of the activating function of Alsin
on either intracellular trafficking or growth cone dynamics (or
both) could be responsible for the motor neuron degeneration
seen in this disorder. A recently described knock-out mouse
model that lacks any working copy of the Alsin gene was found
to have subtle abnormalities of the endosomal pathway as well
as reduced numbers of Purkinje cells and spinal motor neurons,
although clinically, no motor system abnormalities could be
detected at up to 21 months of age [77].
3.2. Senataxin—ALS4
A very large 8 generational pedigree from Maryland,
originally described in 1964 as an unusual form of CMT, and
subsequently designated ALS4, has been linked to a locus at
9q34, [78]. In 2004 heterozygous missense mutations in the
gene Senataxin were found in this family as well as 2 additional
families that had shown linkage to the region [79]. Although a
number of terms have been used to describe this condition,
‘Juvenile ALS’ is probably the most accurate. The condition is
characterised by early onset of a slowly progressive muscle
weakness associated with both UMN signs (hyperreflexia and
extensor planter responses) and LMN signs (distal muscle
wasting that usually affects lower limbs initially and occasion-
ally decreased tendon reflexes). In contrast to sporadic ALS,
and despite the long duration of the condition, respiratory and
bulbar involvement does not seem to occur. Decreased vibration
sense and facial weakness have been reported in a minority of
cases. The age of onset has varied between families. In the
Maryland kindred, the average age was 17 years (range 1–63),
while in the European families onset in infancy or early
childhood was typical [78,80,81]. Electrophysiology is consis-
tent with an axonal disease process affecting predominantly the
motor nerves and post-mortem findings from 2 cases confirmed
loss of motor neurons from the anterior horns and detected
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brainstem [78].
Senataxin was initially identified and named when mutations
in the gene were found to cause Ataxia-Ocular Apraxia 2
(AOA2) [82]. This is an autosomal recessive form of
spinocerebellar ataxia with onset of ataxia in adolescence
accompanied in some cases by apraxia of eye movements,
elevated serum AFP, and impaired proprioception and vibration
sense. Interestingly slowly progressive distal amyotrophy
beginning in the late 1920s is a consistent feature and is a
prominent part of the phenotype leading to early loss of
mobility in some families [83,84]. A total of 17 senataxin
mutations have been found in AOA2 families, 12 of which are
nonsense or frameshift mutations [82,83]. Currently, little is
known about the function of senataxin. Expression is
widespread in human tissues and within the CNS. Senataxin
was originally named because of homology to a yeast protein
Sen1p. Much of the large protein product (2,677 amino acids)
appears to be novel; however sequence at the carboxy-terminal
includes a helicase domain that shows homology to those found
in proteins involved in RNA processing. One protein that shares
this domain is encoded by the gene IGHMBP2 (Immunoglob-
ulin Mu Binding Protein 2), mutations in which have previously
been found to cause autosomal recessive Spinal Muscular
Atrophy with Respiratory Distress (SMARD) [85]. The
presence of this domain suggests that senataxin could belong
to the group of genes associated with motor neuron disorders
with possible roles in mRNA biogenesis or regulation that
includes both IGHMBP2 and SMN1 itself.
3.3. Vamp Associated Protein B—ALS8
A novel linkage to 20q13 was described in 2004 in a large
Brazilian family of Portuguese extraction with a predominantly
lower motor neuron disorder with some unusual additional
features [86]. Patients developed symptoms in the second to
fourth decade; typically either of a postural tremor, fascicula-
tions or painful muscle cramps, before going on to develop
slowly progressive lower motor neuron signs and symptoms in
all limbs. A minority of affected individuals also had upper
motor neuron signs and 7 out of 12 originally reported
individuals eventually developed bulbar involvement prompt-
ing the authors to classify the condition as an atypical form of
ALS. Muscle biopsy showed neurogenic changes and NCVs
were preserved on electrophysiology. The following year a
mutation (P56S) in the gene for VAMP-associated Protein B,
VAPB, was found to be responsible for the disorder in this
family and a further 6 Brazilian families with motor neuron
disorders [87]. A surprising clinical diversity was seen for this
single mutation. While some of the additional patients had a
similar slowly progressing atypical ALS phenotype, in 5
patients from one family, the condition behaved like typical
ALS with malignant progression of both upper and lower motor
neuron symptoms resulting in death in less than 5 years from
first onset of symptoms. In another family the clinical picture
was much milder with onset of lower motor neuron symptoms
in the 4th–6th decade, affecting mainly proximal musclegroups. Pyramidal signs and bulbar involvement were not
present and the postural tremor was uncommon in this group
leading the authors to describe them as a form of adult onset
SMA. All 7 families shared a common haplotype and further
analysis suggests a founding event in the Brazilian population
around the mid-15th century. This event may have been the
occurrence of the mutation itself or the point where a mutation,
previously existing in the Portuguese population, was intro-
duced into the Brazilian population [88]. Although the timing of
this event would fit with first contact between Europeans and
Brazil, so far the mutation has not been reported in the European
population.
VAPB is named for its association with the Vesicle
Associated Membrane Proteins (VAMP) that forms part of the
SNARE complex – the protein machinery involved in vesicle
membrane binding and exocytosis – and is expressed widely in
the CNS and other human tissues [89]. Three human VAMP-
associated proteins are known, all of which share a carboxy
terminal MSP (major sperm protein) domain, a central coiled-
coiled domain, and an amino terminal putative transmembrane
domain that is required for its binding to both VAMP1 and the
homologous VAPA. However, while the orthologues of VAPA
localise to the neuromuscular junction [90] and are involved in
control of neurotransmitter release [91] evidence suggests VAPB
associates with intracellular membranes and microtubules [92]
and may be involved with vesicle tracking in the endoplasmic
reticulum and Golgi apparatus. Introduction of the P56S
mutation in cell culture causes VAPB to lose its normal
association with the ER and form dense cytoplasmic aggregates
[87]. As with other aggregate forming mutations in proteins
associated with motor neuron degeneration it is not yet clear
whether these aggregates are directly neurotoxic, disrupt
fundamental neuronal functions, or act through sequestering
and reducing the function of binding partners. In the case of
VAPB, the binding partners include proteins known to be
essential for neurotransmission.
3.4. Seipin (BSCL2)
The eponym Silver Syndrome has been given to a distinctive
autosomal dominant disorder in which early weakness and
wasting of the intrinsic muscles of the hands is associated with
evidence of upper motor neuron involvement in the form of
increased tone and reflexes in the lower limbs. This constella-
tion of signs and symptoms was first described by J.R. Silver in
1966 in 2 large families [93] one of which was later involved in
establishing linkage to a locus at 11q12–q14, designated SPG17
[94]. This locus was also identified in a family that had been
classified as having distal HMN-type V [95] and in 2004
mutations in the Berardinelli–Seip Congenital Lipodystrophy
gene (BSCL2) were found in both families along with 14 others
from throughout Europe and 1 from Brazil. Two mutations,
N88S and S90L, accounted for all 17 families although
haplotype analysis suggested that the mutations had occurred
independently several times. The Austrian families have now
been shown to share a common ancestor in the 17th century
[96,97]. We have also observed the N88S change as a de novo
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testing a further group of 25 individuals with a Silver Syndrome
phenotype of upper limb amyotrophy and lower limb spasticity
confirming previous observations that this phenotype is
clinically heterogeneous [94,96].
Clinical information from these and a further 4 families that
have been reported has shown considerable variation in the
phenotype [97,98]. The average age of onset of symptoms is
around 20 years but has varied from infancy to the sixth
decade with thenar wasting or gait abnormalities being the
most common initial presentations. Auer-Grumbach et al. [97]
reviewed 90 patients with the N88S mutation and noted a
number of different clinical sub-groups, several of which were
found within the same family in most cases. A number of
mutation positive individuals (average age 43 years, range
13–84) were either unaffected or had sub-clinical abnormal-
ities on testing only. The most common grouping of
symptoms involved prominent weakness and wasting of the
intrinsic muscles of the hands either alone or in association
with a variable degree of pyramidal tract symptoms in the
lower limbs. In some individuals, this pattern was reversed
with muscle wasting and weakness more pronounced in the
lower limbs. In these cases spasticity and other UMN signs
were less prominent and the condition has the appearance of a
form of HMN or SMA. Finally, in some patients, the clinical
picture is dominated by spasticity of the lower limbs with
minimal or absent amyotrophy of the upper limbs and can
appear as a form of Hereditary Spastic Paraplegia. In all
groups, spasticity was associated with foot deformity that was
rated as either severe or very severe in almost a third of
patients. Some exceptional features included decreased or
absent reflexes in the lower limbs in 3 patients and mild
sensory deficits in 7 patients in association with severe motor
involvement. Electrophysiological studies were consistent
with an axonal neuronopathy and reflected the upper limb
predominance.
As its name suggests, BSCL2 was first described in
association with distinct autosomal recessive congenital
lipodystrophy, however, there is no clinical overlap between
this and the neurological disorder and the recessive mutations,
with a single exception, have all been nonsense, frame-shift
insertion/deletion or splice-site mutations [99]. The protein
Seipin is expressed in several tissues but a smaller brain specific
transcript is found in throughout the CNS [96]. The function of
the protein is essentially unknown; analysis of the sequence
suggests an integral transmembrane domain and some homol-
ogy to an AAA ATPase domain found in the much larger gene
Midasin (MDN1), itself a distant evolutionary cousin of Dynein
[100]. The 2 dominant mutations associated with motor neuron
degeneration both disrupt the same N-glycosylation consensus
sequence (N–X–S/T) which is likely to prevent the protein from
adopting its normal tertiary structure. The wild-type protein
shows localisation to the ER, but like a number of the proteins
already discussed, the non-glycosylated mutants have been
found to form dense cytoplasmic aggregates [96]. The
mechanism by which this leads to decreased motor neuron
survival is yet to be determined.3.5. Neurofilament subunit genes (NF-H and NF-L)
Neurofilaments are neuronal specific intermediate filaments
made up light (NF-L), medium (NF-M), and heavy (NF-H)
subunits. The accumulation of neurofilaments, particularly
NF-H, in the cytoplasm and proximal axons of motor neurons is
an early pathological hallmark of sporadic ALS [101].
Mutations in the light subunit, or overexpression of either the
light or heavy subunits in transgenic mice models result in
similar pathological changes in the motor neurons [102,103].
As a result there has been investigation into a possible role for
the human neurofilament genes in ALS but the results remain
uncertain. Studies have focused on the tail domain of NF-H
which contains a repeated amino acid sequence (X–K–S–P–
Y–K), abbreviated as the KSP repeat. Two common alleles
containing 44 (short, S) or 45 (long, L) repeats are found in the
population. Two separate studies have found deletions in the
NF-H tail removing up to 5 KSP repeats in a small percentage of
patients with either sporadic or familial ALS [104,105],
however the same variants were also found in unaffected
family members or unrelated controls. Two smaller studies, one
including familial ALS cases only, have failed to find NF-H
deletions [106,107]. It is possible that deletions in this domain
act as low penetrance predisposing alleles, however Al-Chalabi
et al. noted that in the ALS cases the NF-H allele that did not
contain the deletion was invariably the L allele, while the
unaffected individuals almost always had the S allele [104]
raising the possibility that a length discrepancy between the 2
alleles in complex may be the critical element. This idea is not
supported however by an association study that examined the
distribution of the L and S alleles in a cohort of sporadic ALS
patients in Russia and observed an increase in the SS genotype
in cases versus controls [108]. The role of variants of the NF-H
gene in ALS remains a question requiring investigation. The
neurofilament light subunit has also been implicated in an
inherited dominant disorder characterised by early onset motor
neuron degeneration classified as a form of CMT (CMT2E/
CMT1F) due to the usual co-existence of sensory symptoms,
although these are occasionally absent or limited to reduced
vibratory sense [109–112].
4. Upper motor neuron disorders
4.1. Spastin—SPG4
As the commonest form of dominant pure Hereditary
Spastic Paraplegia (pHSP) a considerable literature exists on
the Spastin gene and its mutations (reviewed [113]). Since it
was shown in 1999 that mutations in Spastin were responsible
for the linkage of pHSP to 2p22–p21 [114] more than 150
mutations have been demonstrated accounting for an estimated
30–40% of dominant pure spastic paraplegia [115,116]. More
recently, 2 studies have found 12–15.5% of sporadic cases,
with a compatible phenotype of pHSP affecting the lower
limbs, had mutations in the spastin gene [117,118]. In some
cases, the apparent sporadic nature is due to a parent being an
asymptomatic carrier and no truly de novo cases were
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asymptomatic and a further 20% are unaware of symptoms
prior to gene testing [119]. This reflects the broad range of age
of onset that has been reported, from infancy to the 9th decade.
Overall more than half mutation carriers will not develop
symptoms until after the age of 30 years although this is not a
function of the type of mutation found in the family [120]. In
the majority of cases the phenotype is of slowly progressive
spasticity in the lower limbs with loss of mobility around 2
decades after the onset of symptoms, although there is good
evidence that the rate of progression is more rapid in patients
with later onset of symptoms [119]. Symptoms found
consistently in a minority of patients include urinary urgency,
upper limb hyper-reflexia or weakness, and decreased
vibration sense or muscle wasting in the lower limbs. Complex
phenotypes have been described in a number of families
segregating with a spastin mutation, including cerebellar
ataxia, epilepsy [121], thinning of the corpus callosum
[122,123], and mental retardation [123]. More significantly,
there is growing evidence that progressive cognitive decline is
a common feature [124–127] first becoming evident by
examination from 40 years of age and progressing to clinically
evident dementia in the 7th–8th decades. This is consistent
with the available post-mortem information that has found that
neuropathological changes extend to many parts of the CNS
[128,129].
The spectrum of mutations found in SPG4 families is
skewed towards truncating and splice site mutations, with
missense amino acid changes accounting for only around 25%
of mutations and clustering strongly in the conserved AAA
cassette ATPase domain [115,119]. Neurons appear to be
unusually sensitive to haploinsufficiency of spastin as splice
site mutations that result in both normal and aberrant splice-
forms of the protein are sufficient to produce the full clinical
picture [130,131]. Investigation of spastin in cell culture
systems has led to varying conclusions about the subcellular
localisation of the wild-type protein depending on the different
methodologies employed (summarised in [113,132]). Staining
for endogenously expressed spastin indicates either a nuclear
localisation [133] or both nuclear and perinuclear cytoplasmic
distribution [134]. In motor neurons, spastin is enriched in
cellular regions where dynamic microtubules are found
including the distal axon [135]. This last finding is consistent
with the growing evidence that spastin has a role in
microtubule turnover.
The AAA ATPase domain of spastin shows homology the
protein katanin that is involved in microtubule disassembly
[136] and evidence suggests there may be a similar relationship
between spastin and microtubules. Transient expression of wild-
type spastin reduces microtubule staining [137] while mutations
that disrupt the ATPase activity of the protein result in spastin
co-localising with the microtubules in a filamentous pattern
[138]. Evans et al. [139] found that the binding of ATP to
spastin promoted this interaction while the ability of the enzyme
to hydrolyse ATP to ADP is required for microtubule severing,
which they were able to directly visualise. This model of
activity is supported by the Drosophila model where theorthologue of spastin is enriched at the synaptic boutons.
Selective RNAi knockdown of the Drosophila protein resulted
in an underdevelopment of the synapses that was reversible
through the action of nocodazole—a microtubule destabilising
agent [140]. A second possible role for spastin is suggested by
the recent finding that spastin interacts with CHMP1B
(Chromatin Modifying Protein 1B), a component of an
endosomal sorting complex required for transport (ESCRT-
III) [132]. This interaction occurs through an amino terminal
MIT domain which shares homology with the MIT domain
found in spartin, the protein mutated in Troyer syndrome
(SPG20); a complicated form of recessive spastic paraplegia in
association with dysarthria, distal muscle wasting, short stature
and developmental delay. Reid et al. note that roles for spastin in
both membrane trafficking and microtubule regulation is not
inconceivable as a single protein may well need to interact with
both transport vesicles and the cytoskeletal structures that
mediate such transport [132].
4.2. Atlastin 1—SPG3A
Mutations in the gene Atlastin were described in 2001 as a
cause of an early onset form of dominant pure spastic
paraplegia, previously linked to chromosome 14q11–q21
[141]. A total of 19 mutations in 32 families have been
described, accounting for an estimated 10% of this phenotype
[141–151]. Onset of symptoms is most commonly in infancy or
early childhood and can impair the development of walking,
however there is wide variation within families and 1 family has
been described in which only adult onset spasticity was found.
Spasticity and increased reflexes are mostly restricted to the
lower limbs but are frequently severe enough to eventually
require walking aids or a wheelchair. Sensory involvement is
limited to decreased vibration but is rare in comparison to
families with spastin mutations. Other CNS involvement has
not been described.
Atlastin is highly expressed in the CNS compared to other
tissues and consistent with the clinical phenotype particularly
high expression is seen in the pyramidal cells of the cerebral
cortex [152]. The protein contains a large GTPase domain that
shares greatest homology with GBP1 (Guanylate Binding
Protein 1)—a member of the dynamin family of GTPases
known to be essential at several stages of vesicle trafficking.
Mutations in another member of this family, dynamin-2, results
in motor neuron degeneration as part of a dominant intermediate
form of CMT [153]. Two genes closely homologous to atlastin
are present in the human genome leading to the renaming of the
original protein atlastin1 [152]. Unlike other members of the
dynamin family atlastin1 also contains a transmembrane
domain and is found as a homo-oligomer localised in the
Golgi apparatus. The reported mutations tend to cluster in the
GTPase domain, including the recurrent R239C mutation that
disrupts an essential RD motif, however their effect on the
localisation and function of atlastin is yet to be examined.
Currently the evidence suggests that atlastin mutations are
likely to affect vesicle trafficking and processing at the Golgi
apparatus.
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Both pure and complicated spastic paraplegia has been
reported in association with recessive mutations in the
paraplegin gene at chromosome 16q24. The condition was
mapped in a large consanguineous family with an adult onset
pure spastic paraplegia, occasionally associated with dysarthria
and optic disk pallor [154]. Mutations in paraplegin have been
demonstrated in a further 6 families, 2 of which have a complex
phenotype with ataxia and cerebellar atrophy on MRI [155–
157]. Onset occurs in the 2nd to 3rd decade and there is slow
progression affecting independent mobility after 20–30 years.
Spasticity and weakness is greatest in the lower limbs and distal
muscle wasting in both hands and feet has been reported.
Paraplegin is a mitochondrial protein and is homologous to
yeast mitochondrial ATPases that are known to form a complex
at the inner mitochondrial membrane with functions including
ATP mediated protein degradation, regulation of splicing and
chaperoning the assembly of respiratory chain proteins [158]. A
knockout mouse missing both copies of the murine homologue
develops a motor phenotype with retrograde degeneration of
axons in the long tracts of the spine and the optic nerve. Prior to
the degeneration of axons hypertrophic and morphologically
abnormal mitochondria are apparent by electron microscopy.
Deficiency of respiratory chain proteins and ATP synthesis is
only seen late in the disease course but accumulation of
neurofilaments, axonal swellings and impairment of retrograde
transport are found at an earlier stage [159]. These observations
point to aberrant intracellular trafficking rather than a deficiency
in oxidative phosphorylation as the critical abnormality despite
the mitochondrial localisation of paraplegin.
4.4. Others (HSP60, KIF5A, NIPA1)
A mutation in HSP60, a mitochondrial chaperone with a
central role in normal protein folding in the mitochondria, is
responsible for a pure dominant spastic paraplegia in a single
large French family (SPG13). The functionally null V72I
mutation was described in 2002 and is associated with a
relatively severe phenotype with frequent involvement of upper
as well as lower limbs [160,161]. Kinesin Heavy Chain (KIF5A)
is a component of the major anterograde motor complex for
axonal transport in neurons [162]. Mutations in KIF5A have
been found in 4 families with a pure lower limb spastic
paraplegia (SPG10) with age of onset varying between late
childhood and adulthood [163–166]. Modeling of the N256S
mutation in Drosophila and yeast orthologues confirms the
expected disruption of anterograde transport resulting in
abnormal cytoplasmic accumulations of organelles and mem-
brane vesicles. Interestingly a mutation in a second kinesin
subunit KIF1Bβ has been associated with the degeneration of
LMNs, along with sensory neurons, in a 3 generational Japanese
family affected by CMT2 [167]. The phenotype associated with
KIF1Bβ has been designated CMT2A1 after mutations in the
gene Mitofusion-2 (MFN2) were found to be a more frequent
cause of CMT2 linking to this region of 1p36 (designated
CMT2A2) [168]. Again mouse models have confirmed theexpected deficits in axonal transport associated with KIF1Bβ
mutations [167]. Also emerging as a cause of dominant pure
spastic paraplegia in multiple families are mutations in the gene
NIPA1 (Non Imprinted in Prader-Willi/Angelman syndrome 1,
SPG6). Six families with juvenile onset have been reported,
with a recurrent mutation at glycine106 found in 4 cases. The
function of the protein product remains unknown but the
presence of 9 transmembrane domains suggests that NIPA1 is
either a receptor or involved in transmembrane transport or
signaling [169–172].
5. Conclusions
5.1. Physical disruption of normal axonal function is a
common theme
As the genes responsible for increasing numbers of familial
forms of motor neuron disorders are identified, analysis of their
function appears to provide continuing confirmation of the areas
of motor neuron vulnerability first suggested by the nature of
the neurons and overlapping aspects of the pathology of ALS
[1]. Principal amongst the recurring themes is that of physical
disruption to intracellular trafficking in the axon. In many
instances the nature of this disruption is obvious and direct, as
with DCTN1 or KIF5A mutations, however evidence is
accumulating that even with proteins not directly involved in
axonal transport secondary effects on axoplasmal flow are
common, as with the sequestration of p150 dynactin in HSPB1
aggregates or the unexpected evidence of early disruption of
retrograde and anterograde transport despite the mitochondrial
localisation of paraplegin. The discovery of connections to
vesicle trafficking and the endosomal transport pathway have
been a feature of recent publications. Direct associations with
this system have been suggested for Alsin, VAPB, Spastin and
Atlastin. In addition mutations in an ESCRT-III component
CHMP2B have recently been described in a family with
frontotemporal dementia (late onset spasticity was also found in
most cases) [173] and mutations in VPS54, a component of the
Golgi-associated Retrograde Protein (GARP) complex, cause a
motor neuron syndrome in mice [174]. The idea that the failure
to transfer essential structural components, trophic factors or
even RNAs up or down the uniquely long axons of motor
neurons could result in dysfunction that demonstrates both cell
type specificity and length-dependent selectivity is an appealing
framework for understanding inherited disorders of the motor
neuron.
5.2. Motor neuron specificity is relative
As well as steadily increasing the number of ‘motor neuron’
associated genes continuing research provides accumulating
experience of the phenotypic variation associated with muta-
tions in each gene. This variation has proved to be extensive,
illustrating in some cases the arbitrary nature of our diagnostic
classifications (Fig. 1). Experience has also shown that rarely, if
ever, is a motor neuron disorder truly restricted to just this
population of neurons. As in sporadic ALS, sub-clinical sensory
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examination. The example of GARS shows that the difference
between presentation as a pure motor neuropathy or as a motor–
sensory neuropathy can be merely a matter of severity and this
may be true for other causes of HMN or CMT2. Involvement of
other parts of the CNS may also be more common than
previously appreciated as illustrated by the examples of
cognitive decline with spastin mutations and the early cranial
nerve involvement seen with mutations in p150 dynactin. These
associations, along with the finding of upper limb predomi-
nance seen with genes such as GARS and BSCL2 suggest that at
least some mechanisms of motor neuron death are more
complicated than can be explained by simple length dependent
models.
5.3. Genetic heterogeneity suggests motor neuron degeneration
is a final common pathway
Despite the growing list of genes associated with motor
neuron disorders many families with clear dominant inheri-
tance of an appropriate phenotype are not found to have
mutations in any of the relevant genes or linkage to known
loci. Even for pure spastic paraplegia families, where spastin
and atlastin gene testing is now widely available around half
the families will not presently acquire a genetic diagnosis. As
research continues it becomes less likely that a gene yet to be
found will account for a very large proportion of any particular
phenotype. Instead the number and variety of genes already
discovered is likely to be at least matched by those yet to be
identified. This heterogeneity leads to the conclusion that at a
genetic level motor neuron degeneration could be a common
final expression of disruptions in a number of cellular systems.
The genetic diversity that has been found to underlie these
Mendelian forms of motor neuron disorders sheds light not
only on the nature of the possible genetic factors that may
predispose to the more common sporadic form of ALS but
also on the high degree of genetic complexity that is likely to
be involved.
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